FOXO3 and cancer: Taken together, given that tumor suppressor p53 is frequently inactivated by missense mutations or deletion in undifferentiated thyroid cancers [27, 28], restoring or increasing FOXO3a transcriptional activity should be an effective strategy for the treatment of such cancers.